SAB Biotherapeutics Target Price

Analysts' average 12-month price target for SAB Biotherapeutics is $11.

Get informed when a big investor buys or sells

+ Follow

Share Price

$3.8

Average Target Price

$11.33

198.2% upside

3 analysts in the last 4 months

High: $13 | Low: $10

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-06-24	BarclaysEliana Merle	$13	242.1% upside
2026-05-20	Jefferies	$11	189.5% upside
2026-05-12	H.C. WainwrightEmily Bodnar	$10	163.2% upside
2026-01-07	UBSMichael Yee	$7	84.2% upside
2025-09-17	Leerink Partners	$7	84.2% upside
2024-06-07	Loop Capital MarketsKumaraguru Raja	$8	110.5% upside
2024-04-02	H.C. WainwrightEdward White	$6	57.9% upside
2022-08-11	Chardan Capital	$3	21.1% downside

SAB Biotherapeutics (SABS) FAQ

SAB Biotherapeutics (SABS) currently reports a target price of $11. Use the charts on this page to explore SAB Biotherapeutics's target price history and peer comparisons.

Analysts' average 12-month price target for SAB Biotherapeutics is $11, about 198.2% upside from the current share price of $3.8. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $11, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for SAB Biotherapeutics, and consider following SABS for alerts when major investors trade the stock.